Cambridge cluster needs talent and funding to sustain growth, warns pharma report

A report commissioned by AstraZeneca (LSE: AZN) has explored the value of life sciences clusters to the UK economy.

The report focuses in particular on the Cambridge cluster, where the global corporate headquarters of the Anglo-Swedish pharma major have been based since May 2016, and claims that it has the potential to contribute an additional £1 billion ($1.35 billion) to the UK economy by 2032.

Of the £32 billion contributed to the UK economy each year by the life sciences sector, almost a third is attributed to businesses and organizations that are co-located closely in these clusters, with Oxford another British example of an area where multiple companies are based.